Elderly patients were more often asymptomatic than younger patients, with 7079 year olds being the least symptomatic. Incidental cases of RCC have recently become more common. Haematuria, hypersedimentation, chronic and systemic symptoms have decreased. Stage, tumour class, gender and age are correlated with symptoms.
In a randomised phase III trial, sunitinib significantly improved efficacy over interferon-alpha (IFN-alpha) as first-line therapy for metastatic renal cell carcinoma (mRCC). We report the final health-related quality of life (HRQoL) results.
Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography
DCEUS is a useful tool for predicting the early efficacy of sunitinib in metastatic renal cell carcinoma patients.
"Natural killer cells taken from a person suffering from melanoma or kidney cancer can be genetically modified. These modified cells when expanded, cultured and reinfused, promise cure when administered with other drugs," said Kumar, who has made substantial contribution in understanding the origin and differentiation of these cells and their role in rejection of transplanted bone marrow.
Renal Cell Carcinoma: Similar Survival Between Combination And Single Therapy, But Longer Remissions In Some Patients
An article published Online First and in an upcoming edition of The Lancet reports that combination therapy for renal cell carcinoma does not improve overall or progression-free survival compared with single therapy using interferon alfa-2a alone. Still, the combined regimen might still have a function because it can produce remissions that are of clinically relevant length in some patients.
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
The study shows that serum levels of VEGF and NGAL are significant predictors of progressionfree survival in patients with renal cell carcinoma treated with sunitinib.
Renal endocrine tumours are extremely rare, and carcinoid tumoral elements in renal cell carcinoma have never been reported. This is the first report of a composite renal cell carcinoma.
The pathology of Wilms' tumour (nephroblastoma): the International Society of Paediatric Oncology approach
In the International Society of Paediatric Oncology renal tumour trials, preoperative chemotherapy has been successfully applied with resulting reduction of tumour rupture and increased favourable stage distribution of nephroblastoma.
New understanding of how cancer cells survive, thrive, and metastasize has enabled researchers to create new targeted therapies for cancer treatments.
Yang et al, (2010) describe the generation and characterisation of an immortalised hereditary leiomyomatosis renal cell carcinoma (HLRCC) cell line, derived from a human patient. HLRCC is a form of inherited kidney cancer in which affected individuals are at risk of developing cutaneous and uterine leiomyomas and kidney cancer, characterized by germline mutation of the Krebs cycle enzyme fumarate hydratase (FH; Launonen et al, 2001). Incidences of renal cancer in HLRCC are highly aggressive and often result in metastasis.